Article
Oncology
Matthew N. Mills, Chelsea Walker, Chetna Thawani, Afrin Naz, Nicholas B. Figura, Sergiy Kushchayev, Arnold Etame, Hsiang-Hsuan Michael Yu, Timothy J. Robinson, James Liu, Michael A. Vogelbaum, Peter A. Forsyth, Brian J. Czerniecki, Hatem H. Soliman, Hyo S. Han, Kamran A. Ahmed
Summary: The combination treatment of stereotactic radiation and T-DM1 is well-tolerated and effective for patients with HER2-positive breast cancer brain metastases. There was no increased risk noted for symptomatic radiation necrosis in this study.
Article
Oncology
David Casadevall, Anna Hernandez-Prat, Sara Garcia-Alonso, Oriol Arpi-Llucia, Silvia Menendez, Mengjuan Qin, Cristina Guardia, Beatriz Morancho, Francisco Javier Sanchez-Martin, Sandra Zazo, Elena Gavilan, Mohammad A. Sabbaghi, Pilar Eroles, Juan Miguel Cejalvo, Ana Lluch, Federico Rojo, Atanasio Pandiella, Ana Rovia, Joan Anabell
Summary: The combination of everolimus and T-DM1 showed strong antitumor effects in HER2-positive breast cancer, potentially due to mTOR-dependent lysosomal processing of T-DM1.
MOLECULAR CANCER RESEARCH
(2022)
Article
Oncology
Claudia Omarini, Federico Piacentini, Isabella Sperduti, Krisida Cerma, Monica Barbolini, Fabio Canino, Cecilia Nasso, Christel Isca, Federica Caggia, Massimo Dominici, Luca Moscetti
Summary: This study used a meta-analysis of real world data to investigate the efficacy of T-DM1 in HER2 positive MBC patients after first-line TP treatment. The results indicate that the efficacy of T-DM1 after TP appears to be similar to that reported in the EMILIA trial. However, more data is needed to confirm the efficacy of T-DM1 in the second-line setting.
Review
Oncology
J. Delgado, C. Vleminckx, S. Sarac, A. Sosa, J. Bergh, R. Giuliani, H. Enzmann, F. Pignatti
Summary: T-DM1, an antibody-drug conjugate, has been approved for the treatment of HER2-positive breast cancer. A study showed that in early breast cancer patients, adjuvant therapy with T-DM1 had better outcomes than trastuzumab, but with more side effects.
Article
Pharmacology & Pharmacy
Jiangping Yang, Jiaqi Han, Yalan Zhang, Muhelisa Muhetaer, Nianyong Chen, Xi Yan
Summary: Through cost-effectiveness analysis, we found that T-DXd is more cost-effective than T-DM1 for patients with HER2-positive metastatic breast cancer in the US, but not in China at current drug prices.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Chenchen Ji, Feng Li, Yang Yuan, Huiqiang Zhang, Li Bian, Shaohua Zhang, Tao Wang, Jianbin Li, Zefei Jiang
Summary: This study compared the efficacy and safety between novel anti-human epidermal growth factor receptor 2 antibody-drug conjugates (ADCs) and trastuzumab emtansine for patients with tyrosine kinase inhibitor (TKI) treatment failure. The results showed that both T-Dxd and other novel anti-HER2 ADCs had significantly better progression-free survival and objective response rate than T-DM1, with tolerable toxicities.
Article
Oncology
Fara Braso-Maristany, Gaia Griguolo, Nuria Chic, Tomas Pascual, Laia Pare, Julia Maues, Patricia Galvan, Maria Vittoria Dieci, Federica Miglietta, Tommaso Giarratano, Olga Martinez-Saez, Mercedes Marin-Aguilera, Francesco Schettini, Benedetta Conte, Laura Angelats, Maria Vidal, Barbara Adamo, Montserrat Munoz, Esther Sanfeliu, Blanca Gonzalez, Ana Vivancos, Patricia Villagrasa, Joel S. Parker, Charles M. Perou, PierFranco Conte, Aleix Prat, Valentina Guarneri
Summary: This study evaluated the association between ERBB2 mRNA expression levels and response and survival following T-DM1 treatment. The results showed that ERBB2 mRNA expression levels were associated with better survival and treatment response.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Editorial Material
Oncology
Alicia F. C. Okines, Nicholas C. Turner
Summary: HER2 amplification heterogeneity is linked to resistance to trastuzumab emtansine in the neoadjuvant setting, highlighting the significance of determining whether varying HER2-positive cancer types require distinct treatment approaches.
Article
Oncology
Carsten Denkert, Chiara Lambertini, Peter A. Fasching, Katherine L. Pogue-Geile, Max S. Mano, Michael Untch, Norman Wolmark, Chiun-Sheng Huang, Sibylle Loibl, Eleftherios P. Mamounas, Charles E. Geyer Jr, Peter C. Lucas, Thomas Boulet, Chunyan Song, Gail D. Lewis, Malgorzata Nowicka, Sanne de Haas, Mark Basik
Summary: In patients with residual invasive breast cancer, T-DM1 reduces the risk of disease recurrence or death compared to trastuzumab. The efficacy of T-DM1 is independent of HER2 expression level and immune activation.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
G. Nader-Marta, D. Martins-Branco, E. de Azambuja
Summary: HER2-positive breast cancer is a subtype of breast malignancy with aggressive behavior and high recurrence rates. The combination of trastuzumab, pertuzumab, and a taxane remains the preferred first-line therapy. Recent studies have shown that trastuzumab deruxtecan is more effective than trastuzumab emtansine as a second-line treatment. Other treatment options include T-DM1, tucatinib, trastuzumab, and capecitabine, as well as trastuzumab with different chemotherapy partners.
Article
Oncology
Elisabeth G. E. de Vries, Josef Rueschoff, Martijn Lolkema, Josep Tabernero, Luca Gianni, Emile Voest, Derk Jan A. de Groot, Daniel Castellano, Gilles Erb, Julia Naab, Margarita Donica, Regula Deurloo, Michiel S. van Der Heijden, Giuseppe Viale
Summary: This study aimed to investigate tumor HER2 expression and its effects on T-DM1 treatment in patients with HER2-positive urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma. The results showed that some HER2-positive bladder cancer and pancreatic cancer patients responded well to T-DM1, and it also provided insight into the prevalence of HER2 positivity and expression patterns in these three non-breast tumor types.
Article
Oncology
Thibaut Sanglier, Alessandra Fabi, Carlos Flores, Evelyn M. Flahavan, Claudia Pena-Murillo, Anne-Marie Meyer, Filippo Montemurro
Summary: Real-world studies suggest that trastuzumab emtansine (T-DM1) may be less effective in patients with metastatic breast cancer who have received prior pertuzumab treatment. However, these studies may have been biased towards selecting patients with more aggressive disease. Our study evaluated the impact of this selection bias and found that patients who entered the study earlier had poorer outcomes compared to those who entered more recently, indicating that selection bias should be considered in treatment assessments.
Article
Oncology
Chiara Molinelli, Francesca Parisi, Maria Grazia Razeti, Luca Arecco, Maurizio Cosso, Piero Fregatti, Lucia Del Mastro, Francesca Poggio, Matteo Lambertini
Summary: T-DM1 has been proven to be an effective and safe treatment option in the adjuvant setting for patients with HER2-positive breast cancer who do not achieve a complete response after standard neoadjuvant chemotherapy plus anti-HER2 targeted therapy. With the availability of more effective anti-HER2 targeted agents, including T-DM1, there is an urgent need for more chemotherapy de-escalation research efforts in the early setting.
EXPERT REVIEW OF ANTICANCER THERAPY
(2021)
Article
Oncology
Shanshan Hu, Yilai Wu, Jiajie Luan, Shuowen Wang, Guorong Fan
Summary: T-DXd demonstrates substantial improvement in HER2-positive metastatic breast cancer, but is not cost-effective compared to T-DM1.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Oncology
Daniele Galanti, Alessandro Inno, Maria La Vecchia, Nicolo Borsellino, Lorena Incorvaia, Antonio Russo, Stefania Gori
Summary: Brain metastases are often associated with HER2+ breast cancer, and systemic therapy with trastuzumab has been the mainstay. Other HER2-targeted agents have been introduced in clinical practice, with newer agents such as neratinib, tucatinib, and trastuzumab deruxtecan showing interesting activity against brain metastases. Further research is needed to elucidate the optimal sequence of these agents and their combination with local treatment.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)